TY - JOUR
T1 - Clinicopathological significance of leucine-rich α2-glycoprotein-1 in sera of patients with pancreatic cancer
AU - Furukawa, Kenta
AU - Kawamoto, Koichi
AU - Eguchi, Hidetoshi
AU - Tanemura, Masahiro
AU - Tanida, Tsukasa
AU - Tomimaru, Yoshito
AU - Akita, Hirofumi
AU - Hama, Naoki
AU - Wada, Hiroshi
AU - Kobayashi, Shogo
AU - Nonaka, Yuji
AU - Takamatsu, Shinji
AU - Shinzaki, Shinichiro
AU - Kumada, Takashi
AU - Satomura, Shinji
AU - Ito, Toshifumi
AU - Serada, Satoshi
AU - Naka, Tetsuji
AU - Mori, Masaki
AU - Doki, Yuichiro
AU - Miyoshi, Eiji
AU - Nagano, Hiroaki
N1 - Publisher Copyright:
Copyright © 2014 by Lippincott Williams & Wilkins.
PY - 2015/1
Y1 - 2015/1
N2 - Objectives: Leucine-rich α2-glycoprotein-1 (LRG-1) is an inflammatory protein. Serum LRG-1 levels can reportedly be used as a cancer biomarker for several types of carcinoma. In the present study, we investigated the clinical usefulness of serum LRG-1 levels as a biomarker of pancreatic cancer. Methods: A total of 124 patients with pancreatic cancer, 35 patients with chronic pancreatitis (CP), and 144 healthy volunteers were enrolled in the study. Serum LRG-1 levels were assayed by enzyme-linked immunosorbent assay. Immunohistochemistry was used to examine LRG-1 expression in pancreatic cancer tissues. Results: Serum LRG-1 levels were significantly increased in patients with pancreatic cancer compared with CP patients and healthy volunteers. The LRG-1 levels increased with progressive clinical stages of pancreatic cancer. Receiver operator curve analysis showed that a combination of carbohydrate antigen 19-9 and LRG-1 resulted in a higher area under the curve for the diagnosis of pancreatic cancer. Positive staining was observed in all cases of pancreatic cancer, but positive signalwas scarcely detected in tissues from CP patients or normal surrounding tissue. Conclusions: These results suggest that serum LRG-1 is a promising biomarker for pancreatic cancer.
AB - Objectives: Leucine-rich α2-glycoprotein-1 (LRG-1) is an inflammatory protein. Serum LRG-1 levels can reportedly be used as a cancer biomarker for several types of carcinoma. In the present study, we investigated the clinical usefulness of serum LRG-1 levels as a biomarker of pancreatic cancer. Methods: A total of 124 patients with pancreatic cancer, 35 patients with chronic pancreatitis (CP), and 144 healthy volunteers were enrolled in the study. Serum LRG-1 levels were assayed by enzyme-linked immunosorbent assay. Immunohistochemistry was used to examine LRG-1 expression in pancreatic cancer tissues. Results: Serum LRG-1 levels were significantly increased in patients with pancreatic cancer compared with CP patients and healthy volunteers. The LRG-1 levels increased with progressive clinical stages of pancreatic cancer. Receiver operator curve analysis showed that a combination of carbohydrate antigen 19-9 and LRG-1 resulted in a higher area under the curve for the diagnosis of pancreatic cancer. Positive staining was observed in all cases of pancreatic cancer, but positive signalwas scarcely detected in tissues from CP patients or normal surrounding tissue. Conclusions: These results suggest that serum LRG-1 is a promising biomarker for pancreatic cancer.
UR - http://www.scopus.com/inward/record.url?scp=84919459079&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84919459079&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000000205
DO - 10.1097/MPA.0000000000000205
M3 - Article
C2 - 25058884
AN - SCOPUS:84919459079
VL - 44
SP - 93
EP - 98
JO - Pancreas
JF - Pancreas
SN - 0885-3177
IS - 1
ER -
